Back to All Collaborations

Building TB Health Systems Capacity in High-Burden Countries

Active Since: 2013

Contributing to SDGs…

Johnson & Johnson is working with governments and other partners in TB high-burden countries to build critical health systems capacity to combat DR-TB – and TB more broadly – in support of the global community’s goal of ending TB.

MEMBER COMPANIES

PARTNER ORGANISATIONS

Objectives

To enable countries to build health systems capacity to introduce the first novel TB medicine in nearly half a century and support the use and scale-up of the medicine in high-burden countries.

What are the health needs and challenges?

Tuberculosis (TB) is the world’s deadliest infectious disease, claiming 1.6 million lives every year. Approximately, 95% of these deaths occur in low- and middle-income countries. Growing resistance to the most commonly-used TB medicines is compounding this challenge. In fact, there are more than half a million cases of drug-resistant tuberculosis (DR-TB) every year, and DR-TB is now the leading cause of deaths from antimicrobial resistance (AMR).

DR-TB is a winnable opportunity that must urgently be addressed. Notably, only one in three cases of DR-TB is properly diagnosed, meaning that approximately 400,000 people with DR-TB don’t even know they have it. Every untreated person with DR-TB can infect up to 15 additional people every year, posing a major threat to human health and global health security.

Moreover, a recent report (2019) from the Economist Intelligence Unit, developed with support from Johnson & Johnson, showed that DR-TB also takes a massive economic toll. DR-TB deaths in a single year (i.e., 230,000 in 2017) cost the global economy $17.8 billion in future GDP loss and an additional $3 billion due to work absences.

Partnership activities and how they address needs and challenges

For several years, Johnson & Johnson has been working with governments and other partners in high-burden countries to build critical health systems capacity to combat DR-TB – and TB more broadly – in support of the global community’s goal of ending TB.

In a number of countries – including China, India, South Africa and Ukraine, among others – Johnson & Johnson is supporting a range of capacity-building activities. Areas of focus include improving access to MDR-TB treatment; training health workers on the clinical management of TB; improving local diagnostic capacity to find the “missing” patients; providing nutritional support to TB patients; and raising awareness and reducing stigma around TB at the community level.

Partnership in Action – Example from China

Since 2016, Johnson & Johnson has been partnering with China’s National Health Commission (NHC), Bill & Melinda Gates Foundation and the Chinese Center for Disease Control and Prevention (China CDC) to undertake a New Drug Introduction Program, aimed at ensuring appropriate access to Johnson & Johnson’s MDR-TB treatment.

Additionally, in 2018, Johnson & Johnson launched a collaboration with the NHC, China CDC and diagnostic manufacturer Cepheid aimed at accelerating TB and MDR-TB patient finding in poverty-stricken regions in China. The program aims at helping China achieve a two-fold increase in MDR-TB case finding in pilot areas from 2018-2021.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs
  2. 3.C: Health workforce
  3. 3.D: Global health security 

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals